Search results

Page results

• London hospitals partner up to run event for children and young people with sickle cell disorder at the Tottenham Hotspur Stadium

  North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.

• Charity at UCLH

  Information about our UCLH Charity, charity funds and associated charities.

• UCLH top trust to work at in London – and third best in the country

  Our staff have rated UCLH as the top trust in London to work at, and the third best in the country, during what has been another incredibly challenging year.

• Macmillan Support and Information Service news

  Latest news and developments in the Macmillan Support and Information Service

• Supporting young people with sickle cell at Tottenham Hotspur

  On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.

• Macmillan Support and Information Service events

  Events, classes and workshops at the Macmillan Support and Information Service (MSIS)

• Clinical Research Facility at UCLH awarded £10 million

  The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.

• RESPOND services for healthcare professionals

  RESPOND – Information for healthcare professionals and services working with asylum seekers

• Advice and guidance service at UCLH

  UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.

• First participant in Europe joins new myeloma trial at UCLH

  UCLH has recruited the first patient in Europe for an early phase trial of a potential new medicine for patients that have a specific sub-type of multiple myeloma (MM), a type of bone marrow cancer.